

Lead generation of HER3-ADC for the treatment of metastatic breast cancer



ONCOLOGY	Lead
Product Type	ADC (Antibody Drug Conjugate)
Indication	Metastatic breast cancer
Target	HER3
MoA (Mechanism of Action)	Binds to the HER3 enriched in breast cancer, internalized into the cell and then released the drug to kill the cancer cell.
Competitiveness	<ul style="list-style-type: none"> • Best in class • Highly stable linker technology • Optimized drug to target • Minimized toxicity to immune cell
Development Stage	Lead
Route of Administration	Intravenous injection